Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
09 mai 2024 16h01 HE
|
Oncternal Therapeutics
Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are...
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
02 mai 2024 16h05 HE
|
Oncternal Therapeutics
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
01 mai 2024 09h00 HE
|
Oncternal Therapeutics
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
18 avr. 2024 09h00 HE
|
Oncternal Therapeutics
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
15 mars 2024 09h00 HE
|
Oncternal Therapeutics
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
07 mars 2024 16h01 HE
|
Oncternal Therapeutics
Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to...
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
29 févr. 2024 16h05 HE
|
Oncternal Therapeutics
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
06 févr. 2024 16h30 HE
|
Oncternal Therapeutics
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
01 févr. 2024 09h00 HE
|
Oncternal Therapeutics
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
08 janv. 2024 09h00 HE
|
Oncternal Therapeutics
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...